While GEM kills bladder cancer cells through apoptosis, it also induces a cytoprotective autophagy involving HMGB1-mediated JNK and ERK activation, and targeting this pathway may improve the anticancer efficacy of gemcitabine against bladder cancer. The gene discussed is HMGB1; the disease is urinary bladder cancer.